XERS News and Press, Xeris Pharmaceuticals Inc. From 06/15/20

Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin Study achieved all pri...

Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-...

Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and com...

Xeris Pharmaceuticals ( XERS -6.4% ) enters into a non-exclusive agreement with unlicensed medicine distributor Clinigen Group plc for the supply and distribution of Gvoke (glucagon injection) outside of the U.S. on a "named patient" basis while its marketing application in Europe is und...

Xeris Pharmaceuticals (NASDAQ: XERS ) announces an exclusive agreement with Clinigen Group to manage the supply and distribution of Gvoke outside of U.S. where Gvoke is not currently licensed. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN,...

SIFCO (NYSEMKT: SIF ) +61%  on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Image source: The Motley Fool. Xeris Pharmaceuticals, Inc.   (NASDAQ: XERS) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading

Xeris Pharmaceuticals, Inc. (XERS) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Allison Wey – Senior Vice President-Investor Relations and Corporate Communication Paul Edick – Chairman and Chief Executive Officer Barry Deutsch –...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q1 GAAP EPS of -$0.89 misses by $0.05 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...